Cargando…
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways
Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic agents. Our laboratory has recently reported that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate, is an inhibitor of HDAC. In this study we examined whether PHI is a hypomethylating agent and its effects on myelo...
Autores principales: | Lu, Quanyi, Lin, Xianghua, Feng, Jean, Zhao, Xiangmin, Gallagher, Ruth, Lee, Marietta Y, Chiao, Jen-Wei, Liu, Delong |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2438442/ https://www.ncbi.nlm.nih.gov/pubmed/18577263 http://dx.doi.org/10.1186/1756-8722-1-6 |
Ejemplares similares
-
Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia
por: Zou, Yong, et al.
Publicado: (2012) -
Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin
por: Jiang, Shaohong, et al.
Publicado: (2010) -
Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells
por: Cang, Shundong, et al.
Publicado: (2016) -
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020) -
Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)